The Efficacy and Safety of Avatrombopag in Patients With End-stage Liver Disease and Thrombocytopenia: A Multicenter, Prospective, Randomized Controlled TrialEAST

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Avatrombopag (Primary) ; Ademetionine butandisulphonate; Glutathione; Glycyrrhizin; Hepatocyte growth factor
Indications Thrombocytopenia
Focus Therapeutic Use
Acronyms EAST

02 Jun 2021 New trial record
01 Jun 2021 Planned End Date changed from 17 Dec 2023 to 31 Dec 2022.
01 Jun 2021 Planned primary completion date changed from 17 May 2023 to 31 Dec 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com